对EORTC QLQ-C30和FACT-G在瘤学中的有意义变化值的审查
Nathan A Clarke1, Julia Braverman2, Gill Worthy1
1Statistics and Programming, Adelphi Values, Bollington, Cheshire, England, UK.
概括
这次审查发现,在癌症试验中,欧洲癌症研究和治疗组织生命质量问卷核心30 (QLQ-C30) 的个性化有意义变化值正在转变. 建议使用当代值,而不是较旧的一般值,以更好地评估患者的结果.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 健康 结果 研究 研究 结果
背景情况:
- 有意义的变化值对于解释癌症临床试验中患者报告的结果至关重要.
- 对于欧洲癌症研究和治疗组织的生活质量问卷核心30 (QLQ-C30) 和癌症治疗的功能评估 - 一般 (FACT-G) 的现有门有所不同.
- 需要了解目前为血液和固体瘤建立这些值的趋势.
结论:
- 试验人员应优先考虑QLQ-C30终点的当代值,而不是QLQ-C30终点的传统值.
- 如果可用,建议使用来自相似患者群体的值.
- 需要进一步的研究,以在更广泛的癌症类型中建立当代值.
相关概念视频
Cancer Survival Analysis
353
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
353
Comparing the Survival Analysis of Two or More Groups
195
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
195


